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Background: Length of hospital stay (LOS) in patients with community-acquired pneumonia (CAP) is variable and
directly related to medical costs. Accurate estimation of LOS on admission and during follow-up may result in
earlier and more efficient discharge strategies.
Methods: This is a prospective multicenter study including patients in emergency departments of 6 tertiary care
hospitals in Switzerland between October 2006 and March 2008. Medical history, clinical data at presentation and
health care insurance class were collected. We calculated univariate and multivariate cox regression models to
assess the association of different characteristics with LOS. In a split sample analysis, we created two LOS prediction
rules, first including only admission data, and second including also additional inpatient information.
Results: The mean LOS in the 875 included CAP patients was 9.8 days (95%CI 9.3-10.4). Older age, respiratory rate
>20 pm, nursing home residence, chronic pulmonary disease, diabetes, multilobar CAP and the pneumonia severity
index class were independently associated with longer LOS in the admission prediction model. When also
considering follow-up information, low albumin levels, ICU transfer and development of CAP-associated
complications were additional independent risk factors for prolonged LOS. Both weighted clinical prediction rules
based on these factors showed a high separation of patients in Kaplan Meier Curves (p logrank <0.001 and <0.001)
and a good calibration when comparing predicted and observed results.
Conclusions: Within this study we identified different baseline and follow-up characteristics to be strong and
independent predictors for LOS. If validated in future studies, these factors may help to optimize discharge
strategies and thus shorten LOS in CAP patients.Background
Community-acquired pneumonia (CAP) is a major cause
for hospitalization and has a substantial impact on
health care costs [1]. Therefore, economic and rational
management of CAP should include discharge of
patients as early as possible without exposing them to
the risk for worsening or recurrent infection. Current
guidelines recommend discharging patients as soon as
they are clinically stable, have no other active medical
problems, and have a safe environment for continued
care [2]. Still, length of hospital stay (LOS) is variable* Correspondence: happy.mueller@unibas.ch
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distribution, and reproduction in any mediumand arbitrary in different settings. For example, in Switz-
erland LOS in patients with CAP was only reduced by
1.2 days over the last 10 years [3]. In an ageing patient
population, social, functional and nursing-related factors
may become increasingly important and early discharge
planning including organization of help and/or nursing
assistance at home becomes more important for short-
ening LOS [4]. In this context, early information of
patients and their families about time management and
expected duration of LOS is of particular importance
and may help to optimize early discharge strategies.
There are a number of well validated clinical scores
which predict 30-day mortality and have shown to im-
prove initial-site-of-care decisions [5-7]. However, there
is no similar instrument for prediction of LOS.entral Ltd This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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with LOS have been reported [8-11]. Some predictors
directly relate to the acute disease or underlying comor-
bidities, while other factors include the social situation
of the patient. Yet, a reliable clinical prediction rule
which helps physicians estimating LOS based on these
and other factors is missing.
The aim of the present study was to propose a LOS
prediction rule in a well characterized cohort of CAP
patients from six different Swiss hospitals, one only fo-
cusing on admission parameters and one also consider-
ing follow up information. Furthermore, we investigated
whether type of medical insurance was associated with
LOS. One could assume that privately insured patients
have shorter LOS because they may have priority for
diagnostic studies, are more easily being transferred to
post acute care centers and are treated by more experi-
enced physicians. On the other hand, financial incentives
could lead to higher LOS in patients, particularly in a
pay-for-service health care system such as in Switzerland.
Methods
Study design and setting
Herein, we used the clinical data from all patients with
CAP enrolled in the multicenter ProHOSP study [12].
The design of this study has been reported in detail else-
where [12]. In brief, from October 2006 to March 2008,
a total of 1359 consecutive patients with presumed lower
respiratory tract infection (LRTI) from six different hos-
pitals located in the northern part of Switzerland were
included. In total, 925 patients had the definite diagnosis
of CAP. Patients were randomly assigned to an interven-
tion group, where guidance of antibiotic therapy was
based on procalcitonin cut-off ranges, and to a standard
group in which guidance of antibiotic therapy was based
on enforced guideline recommendations without know-
ledge of procalcitonin. The baseline characteristics for
both groups were similar and both were treated accord-
ing to current guidelines.
Selection of participants
Patients had to be over 18 years old with a definite diag-
nosis of CAP to be eligible for this analysis. Inclusion
criteria included the presence of at least 1 respiratory
symptom (cough, sputum production, dyspnea, tachyp-
nea, pleuritic pain), plus at least 1 finding during auscul-
tation (rales, crepitation), or 1 sign of infection (core
Body temperature >38.0°C, shivering, or Leukocyte
count >10000/μL or< 4000/μL) independent of anti-
biotic pretreatment. CAP was defined as a new infiltrate
on chest radiograph. Exclusion criteria included patients
with active intravenous drug use, severe immunosup-
pression other than corticosteroid use, life-threatening
medical comorbidities leading to possible imminentdeath, patients with hospital acquired pneumonia and
patients with chronic infection necessitating antibiotic
treatment. We only included patients who survived their
hospital stay for this analysis, as early death would in-
duce a bias for LOS prediction. Patients were examined
on admission to the emergency department by a resident
supervised by a board-certified specialist in internal
medicine. The standardized baseline assessment
included medical history, clinical examination, lab tests
and chest X-ray. For all patients with CAP, the PSI and
the CURB65 was calculated on admission as described
elsewhere [6,7]. The study protocol was approved by all
local ethical committees, and written informed consent
was obtained from all participants.
Study endpoints and selection of covariates
The primary endpoint of this analysis is LOS defined as
the time from hospital admission to hospital discharge.
We recorded baseline data including demographic char-
acteristics (age, gender), comorbid diseases, and living
situation (at home, nursing home residents or living with
continuous nursing support at home), insurance status,
clinical presentation on admission and initial results
from blood analysis. All patients were followed until
hospital discharge and we further assessed adverse
events during the hospital stay including need for ICU
admission and development of CAP specific complica-
tions (empyema).
Statistical analysis
Variables are presented as medians and interquartile
range and a two group comparison was made with Wil-
coxon-MWU tests. In a first step, we assessed the asso-
ciation of different baseline characteristics with LOS in
univariate Cox regression models with time to hospital
discharge of patients as the endpoint of interest. For the
time to event analysis, patients were censored at the
time of hospital discharge. Further, we calculated multi-
variate Cox regression analysis adjusted for all covariates
to assess which parameters had an independent associ-
ation with longer LOS. Of note, hazard ratios (HRs)
lower than 1 correspond to an association of the factor
with longer LOS, while high HRs correspond to earlier
discharge. The proportional hazards assumption of Cox
regression models was evaluated by graphical display
and analysis of the scaled Schoenfeld residuals as recom-
mended [13]. In a 50:50 split sample analysis, we used
all independent predictors from the multivariate model
to calculate two weighted clinical decision rules assign-
ing points to each predictor based on the magnitude of
association (i.e. HR 0.8-0.9 = 1 point, 0.7-0.8 2 points,
0.6-0.5 = 3 points, <0.5 = 4 points); the prediction of
based on the first 50 % of CAP patients was then used
to predict LOS in the second half of patients to assess
Table 1 Baseline characteristics and outcomes of
surviving CAP patients (n = 875)
Characteristics Value n = 875
Demographic characteristics 72 (57–82)
Age (years) 511 (58 %)
Sex (male) - no. (%)
Past Medical history 291 (33 %)
History of chills 628 (72 %)
Former or current smoker 326 (37 %)
Regular alcohol consumption
Social situation at home 580 (66 %)
Lives independently 295 (34 %)
Nursing home resident or living with continuous nursing
help at home
Coexisting illnesses - no. (%) 143 (16 %)
Chronic heart failure 258 (29 %)
Chronic pulmonary disease 152 (17 %)
Diabetes 107 (12 %)
Malignancy
Clinical findings 64 (7 %)
Confusion - no. (%) 313 (36 %)
Respiratory rate> 20 breaths/minute 24 (3 %)
Systolic blood pressure <100 mmHg 312 (36 %)
Heart rate> 100 beats/minute 328 (37 %)
Body temperature> 38.5°C
PSI points 92 (68–116)
PSI class- no. (%) 450 (51 %)
I, II, III 323 (37 %)
IV 102 (12 %)
V
Data are presented as medians (IQR) or absolute numbers (%).
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sidered baseline criteria only, and a second model also
considered factors during follow up. To illustrate the as-
sociation of this rule and LOS, we displayed data in
Kaplan Meier survival curves stratified by the number of
predictors.
In a sensitivity analysis we also investigated whether
randomization of the initial study had an effect on this
analysis. We found no association of the intervention on
LOS (HR 1.05, 95%CI 0.92-1.20). Also, when including
an interaction term into the regression model, we found
no evidence of effect modification. Therefore treatment
assignment was not further considered in this analysis.
All testing was two-tailed and P values less than 0.05
were considered to indicate statistical significance. All
calculations were performed using STATA 9.2 (Stata
Corp, College Station, Texas).
Results
Patient population
From a total of 925 patients, 875 (94.6 %) patients sur-
vived their hospital stay and were included in the further
analysis. Baseline characteristics of the study cohort are
presented in Table 1. The median age of the patients at
the time of study enrolment was 72 years and 42 % were
women. Patients had important comorbidities including
chronic pulmonary disease in 29 %, congestive heart fail-
ure in 16 % and diabetes in 17 %. A total of 49 % of
patients were classified in high risks PSI classes IV or V.
Predictors for LOS in univariate models
A total of 5 % of patients were not hospitalized. The
mean LOS of the overall cohort was 9.8 days (95%CI
9.3-10.4). We assessed LOS in Cox regression models
where low HRs correspond to an association of the fac-
tor with longer LOS. Older age, respiratory rate
>20 pm, confusion, residing in a nursing home, or need
for regular nursing assistance at home, as well as differ-
ent pre-existing comorbid conditions including chronic
pulmonary disease, congestive heart failure and diabetes
showed a significantly decreased chance to be discharged
from the hospital in the univariate Cox regression ana-
lysis (Table 2). Furthermore, markers of high disease se-
verity such as high procalcitonin levels >0.5ug/L, high
CRP levels >150 mg/dL and PSI class were associated
with longer time until hospital discharge. Similarly, posi-
tive blood cultures and multilobar CAP, as well as devel-
opment of empyema or admission to the ICU during the
hospital stay were also significantly associated with
higher LOS.
Predictors for LOS in multivariate models
Using a 50:50 split sample analysis approach, we calcu-
lated two multivariate prediction models: one for factorsbeing present on hospital admission only, and one with
all factors on admission and during hospital stay
(Table 3). In the admission only model, older age, re-
spiratory rate >20 pm, nursing home residence, chronic
pulmonary disease, diabetes, multilobar CAP and the
pneumonia severity index class were independently asso-
ciated with longer LOS. We calculated a weighted pre-
diction score assigning points based on the magnitude
of association. This was also confirmed in Kaplan Meier
curves for time to hospital discharge, where more points
were associated with significantly longer time until hos-
pital discharge (p logrank <0.001) (Figure 1). This pre-
diction rule also showed a good calibration when used
in the validation cohort (Figure 2).
An overall model including not only baseline factors,
but also follow up information, namely blood culture
results, need for ICU admission and development of
complications (empyema) was also calculated. Both,
Table 2 Univariate cox regression model for time to
hospital discharge
Parameters HR (95%CI) p
Demographics
Female Gender 0.95 (0.83-1.08) 0.41
Age (age <60 Reference group)
Age 60–70 years 0.63 (0.52-0.77) <0.001
Age 70–80 years 0.52 (0.43-0.63) <0.001
Age >80 years 0.46 (0.38-0.55) <0.001
Past medical history
Fever (Temp> 38.5°C) 0.82 (0.71-0.95) 0.01
Active smoker 0.85 (0.73-0.98) 0.03
Regular alcohol consumption 1.15 (1.01-1.31) 0.05
Clinical presentation
BP systolic< 90 mmHg 0.67 (0.44-0.99) 0.05
BP diastolic< 60 mmHg 0.77 (0.54-10.7) 0.22
Pulse> 100 bpm 0.93 (0.81-1.07) 0.32
Temperature >38.5 or< 36°C 1.01 (0.88-1.15) 0.93
Respiratory rate> 20 bpm 0.72 (0.62-0.82) <0.001
Confusion 0.76 (0.59-0.99) 0.04
Situation at home




Chronic pulmonary disease 0.75 (0.65-0.86) <0.001
Chronic heart failure 0.68 (0.57-0.81) <0.001
Diabetes 0.8 (0.67-0.95) <0.001
Tumor 0.89 (0.73-1.09) 0.22
Chronic renal failure 0.73 (0.62-0.86) <0.001
Type of medical Insurance
Private insurance 1.1 (0.93-1.3) 0.29
Initial blood analysis
Procalcitonin (<0.1 ng/L Reference group)
Procalcitonin 0.1-0.25 ng/L 0.97 (0.77-1.21) 0.76
Procalcitonin 0.25-0.5 ng/L 0.78 (0.6-1.01) 0.06
Procalcitonin >0.5 ng/L 0.69 (0.56-0.85) <0.001
C-reactive protein (<50mg/L Reference group)
C-reactive protein 50–100 mg/L 0.76 (0.6-0.96) 0.02
C-reactive protein 100–150 mg/L 1.03 (0.82-1.28) 0.82
C-reactive protein> 150 mg/L 0.78 (0.65-0.94) 0.01
Initial albumin level <30 g/L 0.80 (0.67-0.96) 0.02
Initial sodium <130 or >140 mmol/L 0.89 (0.76-1.04) 0.17
Severity of CAP
Bacteremic CAP 0.74 (0.58-0.95) 0.02
Multilobar CAP 0.73 (0.56-0.93) 0.01
Development of empyema 0.41 (0.28-0.6) <0.001
ICU transfer during hospitalisation 0.45 (35–0.59) <0.001
Table 2 Univariate cox regression model for time to
hospital discharge (Continued)
Pneumonia severity index
PSI class (per increase in PSI class) 0.71 (0.66-0.75) <0.001
Of note, hazard ratios (HRs) lower than 1 correspond to an association of the
factor with longer LOS, while high HRs correspond to earlier discharge.
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tions (empyema), as well as initial albumin level were
strong LOS predictors while multilobar CAP did not
reach statistical significance in this second model. A
weighted score based on these factors showed again a
high discrimination of LOS and a good calibration when
used in the validation cohort.Discussion
We identified several factors on admission and during
follow-up, which were independently associated with
longer LOS in patients with CAP. Integrated into a clin-
ical prediction rule, these factors were able to predict
LOS in a split sample analysis and showed high separ-
ation of LOS.
Previously different predictors for LOS have been
reported [5,8-11]. Some predictors directly relate to the
acute disease or underlying comorbidities, while other
factors focus on the social situation of the patient. Pre-
dictors for LOS associated with the acute infection were
abnormal blood results (low PaO2, low albumin, sodium
imbalance), clinical signs of severity (low diastolic blood
pressure, respiratory acidosis, high fever, confusion) or
severity markers such as pleural effusion, multilobar
lung involvement and positive blood culture, or develop-
ment of complications such as empyema requiring
drainage and admission to the ICU [5-8]. Important
comorbidities were regular alcohol consumption, dys-
phagia, chronic renal failure, neoplastic disease, urinary
catheterization, secondary urinary tract infection among
others [8-11]. Important social factors included the as-
sessment of the family caregiver’s involvement, active
and early involvement of the family in the discharge
process, effective communication with the family, the
provision of adequate information and education during
the discharge process among others [4]. Within the pre-
sented study, we were able to evaluate both, factors fo-
cusing on the acute illness on admission and during
follow up and social factors. In multivariate models, we
identified independent LOS predictors which allowed in-
dividual LOS prediction. Thereby, our study expands
previous efforts and proposes a clinical prediction rule,
which may help physician to better estimate LOS in
patients.
Our study population had a mean LOS of 9.8 days,
which is longer than in most similar cohorts in the
Table 3 Multivariate models for prediction of Length of stay
Parameters Initial Prediciton model Follow-up Prediciton model
HR (95%CI) p Points HR (95%CI) p Points
Age (age <60 Reference group)
Age 60–70 years 0.81 (0.59-1.11) 0.187 1 0.74 (0.54-1.01) 0.06 2
Age 70–80 years 0.65 (0.46-0.92) 0.014 3 0.59 (0.42-0.82) 0.002 4
Age >80 years 0.65 (0.46-0.92) 0.015 3 0.53 (0.37-0.76) <0.001 4
Past medical history
Fever (Temp> 38.5°C) 1.1 (0.89-1.36) 0.372 1.16 (0.93-1.44) 0.181
Active smoker 1.04 (0.82-1.33) 0.745 0.98 (0.76-1.24) 0.839
Regular alcohol consumption 1.22 (0.89-1.51) 0.261 1.36 (0.91-1.69) 0.34
Clinical presentation
BD systolic< 90 mmHg 0.78 (0.46-1.32) 0.348 1.29 (0.74-2.25) 0.362
Respiratory rate> 20 pm 0.76 (0.61-0.95) 0.014 2 0.74 (0.6-0.92) 0.006 2
Confusion 0.99 (0.69-1.41) 0.939 1.03 (0.72-1.48) 0.855
Situation at home
Nursing home* 0.84 (0.67-1.06) 0.138 1 0.72 (0.57-0.92) 0.008 2
Comorbid condition
Chronic pulmonary disease 0.70 (0.56-0.87) <0.001 3 0.65 (0.52-0.81) <0.001 3
Congestive heart failure 0.94 (0.71-1.24) 0.645 0.94 (0.71-1.24) 0.655
Diabetes 0.77 (0.59-1.01) 0.062 2 0.68 (0.51-0.89) 0.006 3
renal failure 0.99 (0.76-1.29) 0.956 1.19 (0.9-1.56) 0.214
Initial blood analysis
Procalcitonin (<0.1 ng/L Reference group)
Procalcitonin 0.1-0.25 ng/L 1.36 (0.97-1.89) 0.072 1.31 (0.94-1.84) 0.111
Procalcitonin 0.25-0.5 ng/L 1.77 (0.88-2.64) 0.151 1.86 (0.85-2.79) 0.221
Procalcitonin >0.5 ng/L 1.12 (0.8-1.58) 0.5 1.24 (0.88-1.76) 0.217
C-reactive protein (<50mg/dl Reference group)
C-reactive protein 50–100 mg/dl 0.89 (0.63-1.28) 0.537 0.97 (0.68-1.39) 0.882
C-reactive protein 100–150 mg/dl 1.06 (0.76-1.46) 0.735 1.07 (0.77-1.48) 0.701
C-reactive protein> 150 mg/dl 0.76 (0.57-1.01) 0.057 0.87 (0.65-1.15) 0.325
Nutrition marker
Initial albumin level <30 g/dl 0.81 (0.6-1.08) 0.153 0.77 (0.58-1.03) 0.082 2
Severity of CAP
Multilobar CAP 0.68 (0.45-1.03) 0.066 3 0.92 (0.61-1.38) 0.684
Pneumonia severity index (per increase in class) 0.79 (0.69-0.91) <0.001 2 0.81 (0.7-0.93) 0.003 1
Follow up history not available on admission
Positive blood cultures 0.89 (0.62-1.27) 0.509
ICU transfer during hospitalisation 0.43 (0.29-0.66) <0.001 5
Development of empyema 0.33 (0.19-0.57) <0.001 6
*or needing regular nursing assistance at home.
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portantly, the mean age of the population was 72 years of
age with a high burden of comorbidities. As many
patients needed post-acute care nursing assistance, LOS
was not only dependent on the resolution of the acutedisease, but also on organizational reasons. In line with
this, we found that being a nursing home resident or
needing regular nursing assistance at home was an inde-
pendent predictor for LOS. Also, younger patients may
present with a much more pronounced inflammatory
Figure 1 Association of factors present on hospital admission and duration of hospital stay. Points refer to a weighted-risk score based on
age (3 points), high respiratory rate >20 pm (1 point), being a nursing home resident or need for regular outpatient nursing assistance at home
(1 point), chronic pulmonary disease (1 point) and congestive heart failure (1 point) and multilobar CAP (1 point).
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patients. This is also in accordance with previous studies
that found no difference in LOS despite reducing anti-
biotic courses with the use of a procalcitonin algorithm
[12,14-16].
Increasing health care cost put an important burden
on all health care systems. Inpatient management is up
to 20 times more expensive than outpatient treatment
[11,17-20]. Safely reducing the number of inpatient days
is cost-effective and important from a societal perspec-
tive. As a result of continuous research organizational
and financial pressure [21-29], LOS in CAP patients has
continuously been declining in the past 20 years whilemaintaining and improving quality of care [20,30]. Im-
portantly, previous research suggested that early dis-
charge planning is effective and has the potential to
markedly reduce LOS [31,32]. Our predictive rules may
help clinicians to optimize discharge planning by indi-
cating the expected LOS and indentifying important fac-
tors influencing LOS.
An interesting finding of our study was that private in-
surance status was not associated with LOS. This was
also true when adjusting for age, complications and other
potential confounders. This suggests that although Switz-
erland still had a pay-for-service health care system,
patients with non-private insurance received similar
Figure 2 Calibration of prediction rule on admission (A) and during follow up (B): predicted LOS from derivation cohort and observed
LOS in validation cohort. Points refer to a weighted-risk score based on age (3 points), high respiratory rate >20 pm (1 point), being a nursing
home resident or need for regular outpatient nursing assistance at home (1 point), chronic pulmonary disease (3 point), ICU transfer during
hospitalization and development of empyema (3 point).
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insured patients and there was no evidence of “extended-
hospitalization” of privately insured patients.
Our study has several limitations. First, as a secondary
analysis, we did not evaluate all known predictive factors
for LOS such as respiratory acidosis, dysphagia, urinarycatheterisation and secondary urinary tract infection and
several social factors. Similarly, time to antibiotics and
corticosteroid use was not assessed which may influence
LOS. Second, this study only included Swiss hospitals
which may limit external validity for other countries.
Also, we did not assess time to clinical stability where
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facilities were available without limitations. Thus, our
prediction rule may not apply unconditionally to other
health care systems. LOS in this study was shorter than
the average LOS for patients with CAP in Switzerland in
the same years, but still higher than reported in similar
CAP cohorts within the United States [3]. Third, our re-
sult may not be valid in all patients with CAP as the ori-
ginal ProHOSP trial had exclusion criteria, such as
immune-suppression and dementia. Thus, we consider
this study more hypothesis-generating than definite and
future studies must validate our findings. Importantly,
we encourage future interventional studies to investigate
whether the use of our score for LOS prediction trans-
lates into shorter LOS without adverse effects on
patient’s outcomes.
Conclusion
In conclusion, we created a baseline and a follow-up pre-
diction rule that accurately estimated LOS in CAP
patients. If confirmed in future trials, knowledge of these
factors may help to improve discharge management and
avoidance of prolonged hospitalizations due to non-med-
ical reasons.
Competing interest
No commercial sponsor had any involvement in design and conduct of this
study, namely collection, management, analysis, and interpretation of the
data; and preparation, decision to submit, review, or approval of the
manuscript.
MCC, WA, BM and PS received support from BRAHMS/Thermofisher to
attend meetings and fulfilled speaking engagements. BM has served as a
consultant and received research support. All other authors declare that they
have no competing interests.
Acknowledgements
We thank all members of the ProHOSP Study Group for their important help
during the study. We are grateful to the Data Safety and Monitoring Board,
namely A.P.Perruchoud, S.Harbarth and A.Azzola for continuous supervision
of this trial and all local physicians, the nursing staff, the patients and their
relatives who participated in this study. Especially, we thank the staff of the
emergency room, medical clinics and central laboratories of the University
Hospital Basel, the Cantonal Hospitals Liestal, Aarau, Luzern and
Muensterlingen and the “Buergerspital” Solothurn for their very helpful
assistance, patience and technical support. The ProHOSP Study group
included the following persons: Ursula Schild, RN, Katharina Regez, RN, Rita
Bossart, RN, Robert Thomann, MD, Claudine Falconnier, MD, Marcel Wolbers,
PHD, Stefanie Meyer-Neidert, MD, Thomas Fricker, MD, Claudine Blum, MD,
Ronald Schoenenberger, MD, Christoph Henzen, MD, Thomas Bregenzer, MD,
Claus Hoess, MD, Martin Krause, MD, Heiner C. Bucher, MD, Fabian Mueller,
Jeannine Haeuptle, Roya Zarbosky, Rico Fiumefreddo, Melanie Wieland, RN,
Charly Nusbaumer, MD, Andres Christ, MD, Roland Bingisser, MD, Kristian
Schneider, RN, Christine Vincenzi, RN, Michael Kleinknecht, RN, Brigitte Walz,
PhD, Verena Briner, MD, Dieter Conen, MD, Andreas Huber, MD, Jody
Staehelin, MD, Aarau, Chantal Bruehlhardt, RN, Ruth Luginbuehl, RN, Agnes
Muehlemann, PhD, Ineke lambinon and Max Zueger, MD
Author details
1Department of Internal Medicine, Division of Endocrinology, Diabetes and
Metabolism, University Hospital Basel, Basel, Switzerland. 2Medical University
Clinic, Kantonsspital Liestal, Liestal, Switzerland. 3Medical University Clinic,
Kantonsspital Aarau, Aarau, Switzerland. 4Harvard School of Public Health,
Boston, USA.Authors’ contributions
PS, MCC, WZ and BM had the idea, wrote the protocol and initiated the
study. ISW, WZ, BM and PS managed the trial and collected data. ISW and PS
performed the statistical analyses. ISW and PS drafted the manuscript and all
authors amended and commented on the manuscript. All authors approved
the final version.Funding sources
The initial trial was supported by grant SNF 3200BO-116177/1 and by grant
SNF 32003B_135222 from the Swiss National Science Foundation. Dr. Schuetz
was supported by a research grant from the Swiss Foundation for Grants in
Biology and Medicine (Schweizerische Stiftung für medizinisch-biologische
Stipendien, SSMBS, PASMP3-127684/1). Dr. Christ-Crain was supported by a
grant of the Swiss National Science Foundation (PP00P3-12346).
Received: 14 September 2011 Accepted: 20 May 2012
Published: 20 May 2012References
1. Mizgerd JP: Lung infection–a public health priority. PLoS Med 2006, 3(2):
e76.
2. Mandell LA, Wunderink RG, Anzueto A, et al: Infectious Diseases Society of
America/American Thoracic Society consensus guidelines on the
management of community-acquired pneumonia in adults. Clin Infect Dis
2007, 44(Suppl 2):S27–S72.
3. http://www.bfs.admin.ch/bfs/portal/de/index, http://www.bfs.admin.ch/bfs/
portal/de/index.html: Bundesamt für Statistik S, Bundesamt für Statistik S. Ref
Type: Online Source: editor; 2008.
4. Bauer M, Fitzgerald L, Haesler E, Manfrin M: Hospital discharge planning
for frail older people and their family. Are we delivering best practice? A
review of the evidence. J Clin Nurs 2009, 18:2539–2546.
5. Garau J, Baquero F, Perez-Trallero E, et al: Factors impacting on length of
stay and mortality of community-acquired pneumonia. Clin Microbiol
Infect 2008, 14(4):322–329.
6. Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk
patients with community-acquired pneumonia. N Engl J Med 1997, 336
(4):243–250.
7. Lim WS, van der Eerden MM, Laing R, et al: Defining community acquired
pneumonia severity on presentation to hospital: an international
derivation and validation study. Thorax 2003, 58(5):377–382.
8. Kaysar M, Augustine T, Jim L, Benjamin C: Predictors of length of stay
between the young and aged in hospitalized community-acquired
pneumonia patients. Geriatr Gerontol Int 2008, 8(4):227–233.
9. Masotti L, Ceccarelli E, Cappelli R, Barabesi L, Guerrini M, Forconi S: Length
of hospitalization in elderly patients with community-acquired
pneumonia. Aging (Milano) 2000, 12(1):35–41.
10. Menendez R, Ferrando D, Valles JM, Martinez E, Perpina M: Initial risk class
and length of hospital stay in community-acquired pneumonia. Eur
Respir J 2001, 18(1):151–156.
11. Menendez R, Cremades MJ, Martinez-Moragon E, Soler JJ, Reyes S, Perpina
M: Duration of length of stay in pneumonia: influence of clinical factors
and hospital type. Eur Respir J 2003, 22(4):643–648.
12. Schuetz P, Christ-Crain M, Wolbers M, et al: Procalcitonin guided antibiotic
therapy and hospitalization in patients with lower respiratory tract
infections: a prospective, multicenter, randomized controlled trial. BMC
Health Serv Res 2007, 7:102.
13. Grambsch PM, Therneau TM, Fleming TR: Diagnostic plots to reveal
functional form for covariates in multiplicative intensity models.
Biometrics 1995, 51(4):1469–1482.
14. Schuetz P, Christ-Crain M, Thomann R, et al: Effect of procalcitonin-based
guidelines vs standard guidelines on antibiotic use in lower respiratory
tract infections: the ProHOSP randomized controlled trial. JAMA 2009,
302(10):1059–1066.
15. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al: Effect of procalcitonin-
guided treatment on antibiotic use and outcome in lower respiratory
tract infections: cluster-randomised, single-blinded intervention trial.
Lancet 2004, 363(9409):600–607.
16. Christ-Crain M, Stolz D, Bingisser R, et al: Procalcitonin guidance of
antibiotic therapy in community-acquired pneumonia: a randomized
trial. Am J Respir Crit Care Med 2006, 174(1):84–93.
Suter-Widmer et al. BMC Pulmonary Medicine 2012, 12:21 Page 9 of 9
http://www.biomedcentral.com/1471-2466/12/2117. Aliyu ZY, Aliyu MH, McCormick K: Determinants for hospitalization in "
low-risk" community acquired pneumonia. BMC Infect Dis 2003, 3:11.
18. Coley CM, Li YH, Medsger AR, et al: Preferences for home vs hospital care
among low-risk patients with community-acquired pneumonia. Arch
Intern Med 1996, 156(14):1565–1571.
19. Labarere J, Stone RA, Scott OD, et al: Factors associated with the
hospitalization of low-risk patients with community-acquired pneumonia
in a cluster-randomized trial. J Gen Intern Med 2006, 21(7):745–752.
20. McGregor MJ, Fitzgerald JM, Reid RJ, et al: Determinants of hospital length
of stay among patients with pneumonia admitted to a large Canadian
hospital from 1991 to 2001. Can Respir J 2005, 12(7):365–370.
21. Arnold FW, LaJoie AS, Brock GN, et al: Improving outcomes in elderly
patients with community-acquired pneumonia by adhering to national
guidelines: Community-Acquired Pneumonia Organization International
cohort study results. Arch Intern Med 2009, 169(16):1515–1524.
22. Athanassa Z, Makris G, Dimopoulos G, Falagas ME: Early switch to oral
treatment in patients with moderate to severe community-acquired
pneumonia: a meta-analysis. Drugs 2008, 68(17):2469–2481.
23. Bewick T, Cooper VJ, Lim WS: Does early review by a respiratory physician
lead to a shorter length of stay for patients with non-severe community-
acquired pneumonia? Thorax 2009, 64(8):709–712.
24. Fung HB, Monteagudo-Chu MO: Community-acquired pneumonia in the
elderly. Am J Geriatr Pharmacother 2010, 8(1):47–62.
25. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ: Associations
between initial antimicrobial therapy and medical outcomes for
hospitalized elderly patients with pneumonia. Arch Intern Med 1999, 159
(21):2562–2572.
26. Martinez R, Reyes S, Lorenzo MJ, Menendez R: Impact of guidelines on
outcome: the evidence. Semin Respir Crit Care Med 2009, 30(2):172–178.
27. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN: Guideline-concordant
therapy and reduced mortality and length of stay in adults with
community-acquired pneumonia: playing by the rules. Arch Intern Med
2009, 169(16):1525–1531.
28. Pines JM, Isserman JA, Hinfey PB: The measurement of time to first
antibiotic dose for pneumonia in the emergency department: a white
paper and position statement prepared for the American Academy of
Emergency Medicine. J Emerg Med 2009, 37(3):335–340.
29. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH: Effect of macrolides as
part of initial empiric therapy on length of stay in patients hospitalized
with community-acquired pneumonia. Arch Intern Med 1999, 159
(21):2576–2580.
30. Capelastegui A, Espana PP, Quintana JM, et al: Declining length of hospital
stay for pneumonia and postdischarge outcomes. Am J Med 2008, 121
(10):845–852.
31. Southern WN, Berger MA, Bellin EY, Hailpern SM, Arnsten JH: Hospitalist
care and length of stay in patients requiring complex discharge
planning and close clinical monitoring. Arch Intern Med 2007, 167
(17):1869–1874.
32. Sala E, Alegre L, Carrera M, et al: Supported discharge shortens hospital
stay in patients hospitalized because of an exacerbation of COPD. Eur
Respir J 2001, 17(6):1138–1142.
doi:10.1186/1471-2466-12-21
Cite this article as: Suter-Widmer et al.: Predictors for length of hospital
stay in patients with community-acquired Pneumonia: Results from a
Swiss Multicenter study. BMC Pulmonary Medicine 2012 12:21.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
